ROP
★★☆☆☆ PasstemplateRoper Technologies, Inc.
Technology · sector percentile 46
Session move
$358.57
Vol 0.64× avg
66/100 quant · tgt $439.43
RS60 -3.5% vs SPY · ADV$ 332.1M
pushed 2026-10-07T20:51 · After hours · Pushed snapshot
Since last scan
2026-10-06 → 2026-10-07
Context only — not a buy/sell signal. Built from scan history and cached news/filings.
Snapshot quote
session 2026-10-06 · scan 2026-10-07 · pushed 10-07 16:51 ET · After hours
Show quote fundamentalsHide quote fundamentals
- Last (scan/close)
- $359.54
- Previous close
- $363.38
- Pushed last
- $358.57 · 10-07 16:51 ET · After hours
- Session open
- $360.98
- Last session range
- $359.08 – $364.34
- 52-week range
- $305.19 – $517.59
- Session volume
- 580,081
- Avg volume (20d)
- 900,419
- Market cap
- $35.56B
- PE (TTM)
- 14.98
- Forward PE
- 14.75
- Dividend yield
- 0.98%
- 1y target est.
- $439.43
- Next earnings
- 2026-10-22
Snapshot quote — last daily session bars and scan fundamentals. Not live bid/ask or intraday quotes. Pre/after-hours quotes are thinner and may differ from the regular session.
If you put $1,000.00 in
1y ago
$714.61
−29%
5y ago
$827.11
−17%
Price path only from cached daily closes (adjusted when available). Not dividends cash, fees, or advice.
Market briefing
Curated digest — not a trade signal. Headlines and links as provided by the producer.
- Roche (SWX:ROP) Stock Looks Discounted As Its 60% Run Continues
Roche Holding has delivered a powerful share price run over the last few years, which puts a bright spotlight on whether that market value still lines up with what the group earns. With a string of positive late stage trial results in oncology, neurology and renal disease, the question for you now is how much of that clinical momentum is already reflected in the price. Roche Holding has returned 59.8% over the past 3 years, so a lot of future expectations are already embedded in the current...
Yahoo · 2026-09-23
- Is Roche Holding (SWX:ROP) Undervalued Following Its Phase 3 IgA Nephropathy Win?
Roche Holding (SWX:ROP) is back in focus after partner Ionis reported that sefaxersen met the primary endpoint in the Phase 3 IMAgINATION trial for IgA nephropathy, delivering a statistically significant reduction in proteinuria compared with placebo. The latest clinical headlines come on top of a strong run for Roche Holding, with the share price up 8.32% over 90 days and 11.58% year to date. The 1-year total shareholder return of 44.02% points to momentum that has been building rather than...
Yahoo · 2026-09-23
- Is Roper Technologies Stock Underperforming the Dow?
Roper Technologies has notably underperformed the Dow over the past year, but analysts are cautiously optimistic about the stock’s prospects.
Yahoo · 2026-09-07
Price Chart
Daily prices from cache
Loading price history…
AI Analysis
- Bull Thesis — ROP scores 66.4/100 (Pass) with revenue growth at 8.5% and a multi-factor profile supporting the current ranking.
- Risks — Key risks for ROP include valuation compression, sector rotation, and any deterioration in earnings momentum or balance-sheet leverage. Context: cached next earnings 2026-10-22; disclosure reasons form4_single_ambiguous, item_5_02.
- Target Upside — Consensus implied upside is 22.2%. Category 'Pass' suggests monitoring position sizing against the 100-point model thresholds.
Score History
30 days of scans. Daily batch adds the next weekday automatically while the API is running.
- DatePriceChgScoreRating
- 2026-10-07$359.54−$3.8066.4Pass
- 2026-10-06$363.34+$7.2567.0Pass
- 2026-10-05$356.09−$4.3865.2Pass
- 2026-10-02$360.47+$2.0565.6Pass
- 2026-10-01$358.41+$7.0965.4Pass
- 2026-09-30$351.32+$0.2365.6Pass
- 2026-09-29$351.09−$0.6967.5Pass
- 2026-09-28$351.78−$9.8268.0Pass
- 2026-09-25$361.60−$3.1968.8Pass
- 2026-09-24$364.79+$1.9370.0Watch
- 2026-09-23$362.87−$1.3370.0Watch
- 2026-09-22$364.20−$4.1970.2Watch
- 2026-09-21$368.39−$2.3871.3Watch
- 2026-09-18$370.77−$2.5470.9Watch
- 2026-09-17$373.31−$5.2571.3Watch
- 2026-09-16$378.55−$6.0970.9Watch
- 2026-09-15$384.65−$13.4472.3Watch
- 2026-09-14$398.08+$12.5172.5Watch
- 2026-09-11$385.57−$6.1972.4Watch
- 2026-09-10$391.76+$1.4672.5Watch
- 2026-09-09$390.30−$16.9872.3Watch
- 2026-09-08$407.28$0.0072.0Watch
- 2026-09-07$407.28−$15.0772.0Watch
- 2026-09-04$422.35+$6.5670.7Watch
- 2026-09-03$415.79−$2.5271.3Watch
- 2026-09-02$418.31−$6.3371.0Watch
- 2026-09-01$424.64−$1.5670.5Watch
- 2026-08-31$426.20+$3.5170.4Watch
- 2026-08-28$422.69+$9.4170.7Watch
- 2026-08-27$413.28—71.5Watch
Quant Breakdown
Short volume (FINRA)
Off-exchange short sale volume ratio vs recent sessions — not a squeeze forecast.
- Short / total
- 61.9%
- vs 20d (z)
- -0.74
- Short vol
- 140,299
- Status
- ok
Squeeze pressure score
full40/100
- Short leg
- 28
- Call leg
- 70
- Activity
- 1.1
- Call vol share
- 70.1%
- PCR (vol)
- 0.43
- Call OI share
- 59.5%
- ATM IV
- 46.8%
FINRA off-exchange short volume (TRF/ADF consolidated). Not short interest as % of float. Squeeze pressure score (0–100) — free composite of off-exchange short volume and (when available) call-side options activity. Not a probability that a squeeze will occur.
Disclosure score
Rule-based News / Insider / Earnings legs from cached SEC filings — context only, not beat/miss or a buy signal.
Disclosure score
-12
- News
- -12
- Insider
- 0
- Earnings
- 0
Signals below are rule hits from cached filings — Risk / Constructive / Attention. Attention is not a bullish call. Linked chips open the SEC original when available.
Attention (~)
Disclosure event score — rule-based view of recent SEC filings and earnings calendar. Not a prediction that price will move, and not earnings beat/miss.
Earnings surprise (quant context)
From Yahoo/public fundamentals cached on the last quant scan — not part of the disclosure event score, and not a buy signal. Figure can lag the latest print.
Last reported surprise +2.1%
Filings & events
Recent SEC disclosures and earnings dates — context only, not a trade signal.
- Next earnings
- 2026-10-22yahoo_calendar
- Last earnings
- —
- SEC ↗42026-10-05
4
- SEC ↗8-K2026-10-01
8-K
- SEC ↗42026-09-17
4
- SEC ↗42026-09-17
4
- SEC ↗42026-09-17
4
- SEC ↗8-K2026-08-10
8-K
- SEC ↗10-Q2026-07-31
10-Q
- SEC ↗42026-07-27
4
- SEC ↗42026-07-27
4
- SEC ↗8-K2026-07-23
8-K
SEC filings as reported; earnings dates may come from Yahoo calendar. Context only — not investment advice and not a prediction that price will move on a filing or event.